Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QRX-3 (Neukidney)
- Development stage
- Unknown
- Lead developer
- Neukidney
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**QRX-3** is an investigational oral renal therapy developed by Neukidney for chronic kidney disease. Registered studies describe it as a formulated NAD and NAD+ oxidative-phosphorylation or mitochondrial-availability modulator intended to stabilize renal tubular cells, reduce intracellular oxidative injury, and limit nephron loss. Its precise chemical composition, direct molecular target, and confirmed active ingredient have not been publicly disclosed. QRX-3 should not be conflated with Neukidney's separate biocompatible renal-conduit and platelet-rich-plasma or cellular-therapy programs. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06866236))
- Other names
- Eserenate
Beyond the preview
Go deeper on QRX-3 (Neukidney).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QRX-3 (Neukidney).